Timothy J.R. Harris, Ph.D., D.Sc.
Senior Vice President Translational Medicine & Biochemistry
Founder and Scientific Advisor, is currently the Senior Vice President of Translational Medicine at Biogen Idec in Cambridge, MA. Previously he was CTO and Director of the Advanced Technology Program at SAIC Frederick. Before that he was President and CEO of Structural GenomiX (later SGX Pharmaceuticals) of San Diego, a drug discovery company focused on cancer. Earlier in his career, Dr. Harris was Senior Vice President of Research at Sequana/Axys, where he expanded the research group from ten to over 200 people and secured four corporate deals. From 1989 to 1993, he was Director of Biotechnology at Glaxo Group Research in the United Kingdom, where he held responsibility for global high throughput screening. From 1981 until 1989, Dr. Harris was a senior molecular biologist at Celltech Ltd., a biotechnology company in the UK, cloning various genes coding for therapeutic proteins. Dr. Harris received a Ph.D. and M.S. in General Virology and a B.Sc. in Biochemistry from the University of Birmingham in England. Dr. Harris has an honorary doctorate (D.Sc) from the University of Birmingham, UK awarded in July 2010.